Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,932 recruiting studies in this area right now.
By phase
- Not applicable2,031
- Phase 21,075
- Phase 1791
- Phase 1/Phase 2481
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma179
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Lymphedema49
- Acute Myeloid Leukemia (AML)48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center62
- City of Hope Medical Center58
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California397
- Texas185
- Alabama157
- Maryland152
- Arizona127
- Massachusetts105
- Florida104
- New York96
- Ohio72
- Minnesota69
Recruiting studies4,932 total
- NCT06145581Recruiting
Remote health coaching for older myeloma patients with fatigue
This study tests whether remote monitoring and health coaching can improve quality of life in older adults with multiple myeloma who are experiencing fatigue. You'll use a tablet or smartphone to track symptoms and get support from a coach.
Rochester, MinnesotaAges 65 years+ - NCT03016806Recruiting
Umbilical cord blood transplant from unrelated donors
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
Rochester, New YorkAges 2 months–75 years - NCT00626496Recruiting
Family study for certain blood and immune disorders
This study looks at families where more than one close, blood-related person has a lymphoproliferative disorder (a group of conditions where the lymph system makes too many abnormal cells). It aims to better understand why these disorders run in families and how they may be inherited or related.
Rochester, MinnesotaAges 18–100 - NCT06111638RecruitingPhase 2/Phase 3
Gene therapy for severe hemophilia A
This trial tests a gene therapy to help your body produce more of the clotting protein (factor VIII) it's missing. It may reduce or stop the need for regular factor infusions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06106945RecruitingPhase 1/Phase 2
AZD0305 alone or with other drugs for multiple myeloma
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06122831RecruitingPhase 1/Phase 2
TQ05105 and TQB3617 for myelofibrosis
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
Guangzhou, GuangdongAges 18 years+ - NCT06122389RecruitingPhase 3
Study of SHR2554 for T-cell lymphoma
This trial tests a new drug called SHR2554 (compared to chidamide) for T-cell lymphoma that has not responded to or come back after prior treatment. It's a Phase 3 study to see if the drug can help control the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT06121843RecruitingPhase 1
Study of CAR-T cell therapy in combinations for multiple myeloma
This trial tests a new CAR-T cell therapy (called arlocabtagene autoleucel) combined with other drugs for multiple myeloma that has returned or stopped responding. It aims to find a safe and effective dose while tracking how well the treatment works.
Birmingham, AlabamaAges 18 years+ - NCT06104566RecruitingPhase 3
Study of APG2575 for CLL or SLL patients on BTKi
This trial tests a new drug called APG2575 for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have been taking a BTK inhibitor for at least 12 months. The goal is to see if adding APG2575 can help control the disease better.
Tuscon, ArizonaAges 18–99 - NCT06116110Recruiting
Long-term follow-up after gene therapy treatment
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
Gilbert, ArizonaAges 18 years+ - NCT06106269Recruiting
Outcomes of rectal artery embolization for bleeding hemorrhoids
This study looks at how well rectal artery embolization (a procedure that uses tiny particles to block blood flow to hemorrhoids) works for treating bleeding internal hemorrhoids. It aims to understand if this treatment improves quality of life and reduces symptoms.
Rochester, MinnesotaAges 18–90 - NCT06107738RecruitingPhase 2
Iberdomide and Daratumumab after stem cell transplant for multiple myeloma
This trial tests two medicines, iberdomide and daratumumab, given as maintenance therapy after an autologous stem cell transplant. It is for people with multiple myeloma who still have small amounts of cancer cells detected after transplant and who have already been treated with a daratumumab-containing regimen.
Detroit, MichiganAges 18 years+ - NCT06118372RecruitingPhase 1
Recombinant vWF concentrate for bleeding on ECMO
This trial tests whether a medication called recombinant von Willebrand factor (vWF) can help control major bleeding in adults who are on life support with ECMO. If you are on ECMO and have a serious bleed, this treatment might help stop the bleeding.
Charlottesville, VirginiaAges 18 years+ - NCT06108232RecruitingPhase 2
Study of two drugs for untreated follicular lymphoma
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
Houston, TexasAges 18 years+ - NCT06105554RecruitingPhase 1/Phase 2
Study of belumosudil for relapsed or refractory multiple myeloma
This trial tests a new drug called belumosudil, alone or with dexamethasone, for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to see if it can help when other therapies have stopped working.
Houston, TexasAges 18 years+ - NCT06116032Recruiting
Immune profiling for cancer immunotherapy response
This trial studies immune system changes in cancer patients receiving immunotherapy, such as checkpoint inhibitors or cell therapies. It aims to understand why some people respond better than others.
Lebanon, New HampshireAges 18 years+ - NCT06104592RecruitingPhase 2
Radiation before CAR T-cell therapy for high-risk large B-cell lymphoma
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
Tampa, FloridaAges 18 years+ - NCT06107582Recruiting
Long-term study of children with immune thrombocytopenia
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
TianjinAges 6–17 - NCT06124586Recruiting
Early angioplasty for diabetic foot ulcers
This trial tests if an early procedure to open blocked leg arteries (angioplasty) helps heal foot ulcers in people with type 2 diabetes. It aims to improve blood flow and prevent amputation.
DüsseldorfAges 18 years+ - NCT06128070RecruitingPhase 2
Preventing GVHD after stem cell transplant for leukemia
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Duarte, CaliforniaAges 2–22 - NCT06125743Recruiting
Self-management program for head and neck swelling
This study tests a self-management program to help people with head and neck cancer manage swelling (lymphedema) and tightness (fibrosis) after treatment. It may be a good fit if you have finished cancer therapy, are cancer-free, and have access to internet at home.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02508038RecruitingPhase 1
Test CD19+ depleted donor transplant for hard childhood cancers
This Phase 1 study tests a special type of half-matched (haploidentical) stem cell transplant plus medicines, aiming to reduce cancer relapse after transplant. It may help children and teens with certain leukemia/lymphoma or specific solid tumors who do not have a fully matched donor or whose best options are limited.
Madison, WisconsinAges 7 months–21 years - NCT04986657Recruiting
Whole genome testing to help diagnose AML or MDS
This study checks whether adding whole genome sequencing (reading a person’s DNA more broadly) alongside standard genetic tests improves the diagnosis process for AML or MDS. It may help doctors decide on the best next steps when AML/MDS is suspected.
St Louis, MissouriAges 18 years+ - NCT00230165Recruiting
Genetics and blood testing for inherited bleeding disorders
This study looks at genes and blood function in people with inherited (passed-down) problems with platelets, white blood cells, or blood clotting. It may help improve understanding of the cause of these conditions and how they work in the body.
New York, New YorkAges Any age
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,932 recruiting hematology studies from the U.S. registry right now, out of 7,407 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.